Edit
Thryv Therapeutics
https://www.lqttrx.com/Last activity: 06.01.2022
Probably Closed - Reference to Thryv Therapeutics Inc.
Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat Congenital Long QT Syndromes (LQTS), atrial fibrillation, and resistant cancers with potent and selective
Location: Canada, Quebec, Laval
Employees: 11-50
Total raised: $19M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 08.11.2021 | Lumira Ven... | lumiravent... |
| - | Amzak Heal... | amzakhealt... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.08.2021 | Series A | $19M | - |
Mentions in press and media 8
| Date | Title | Description |
| 06.01.2022 | LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT Syndrome | Closing the gap between industry and academia to place patients directly at the center of research efforts. |
| 01.11.2021 | LQT Therapeutics Announces the Appointment of Dr. Robert Booth to its Board of Directors | Company Strategically Strengthens its Fight Against Long QT Syndrome with Novel Kinase Drug Development Expertise |
| 10.08.2021 | LQT Therapeutics Announces Closing of US$19M Series A Financing to Advance Lead Compound Through Phase 1 while Advancing Portfolio Assets | |
| 10.08.2021 | LQT Therapeutics secures $19M to tackle heart diseases with Sanofi compounds Age-Appropriate Formulation Development for Pediatric Trials-Challenges and Considerations | LQT Therapeutics wants to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with $19 million. Current treatments for Long QT syndrome are meant to prevent erratic hear... |
| 10.08.2021 | Lumira Ventures invests in LQT Therapeutics US$19M Series A financing to advance lead compound through Phase 1 | LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing. LQTT is advancing a series... |
| 10.08.2021 | LQT Therapeutics secures $19M to tackle heart diseases with Sanofi compounds | LQT Therapeutics wants to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with $19 million. The two-year-old Canadian biotech will use the series A, disclosed Tuesda... |
| 09.08.2021 | LQT Therapeutics Announces Closing of US$19M Series A Financing | - |
| - | LQT Therapeutics | “Thryv Therapeutics (previously LQT Therapeutics), has been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019, and our portfolio has evolved to include the treatment of resistant and rare canc... |